Expression of MMP, HPSE, and FAP in stroma promoted corneal neovascularization induced by different etiological factors

Current Eye Research

Volumn 35, Issue 11, 2010, Pages 967-977

  Shi, Weiyun ^a   Liu, Juncai ^a   Li, Man ^a   Gao, Hua ^a   Wang, Ting ^a  

^a SHANDONG EYE INSTITUTE   (China)

Author keywords

Corneal neovascularization; Etiology; FAP; HPSE; MMP; Stroma

Indexed keywords

CD31 ANTIGEN; FIBROBLAST ACTIVATION PROTEIN; GELATINASE A; GELATINASE B; HEPARANASE; MATRIX METALLOPROTEINASE; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TRANSPLANTATION; CHEMICAL BURN; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA STROMA; EYE BURN; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KERATITIS; MALE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; SUTURE; TUMOR CELL;

ANIMALS; CORNEAL NEOVASCULARIZATION; CORNEAL STROMA; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GELATINASES; GLUCURONIDASE; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; SERINE ENDOPEPTIDASES;

EID: 77958487611     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.502294     Document Type: Article

References (34)

1. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273-286. (Pubitemid 46505878)
2. Pakneshan P, Birsner AE, Adini I, et al. Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs. Invest Ophthalmol Vis Sci. 2008;49:3909-3913.
3. Gebhardt BM, Shi W. Experimental corneal allograft rejection. Immunol Res. 2002;25:1-26.
4. Elkin M, Miao HQ, Nagler A, et al. Halofuginone: A potent inhibitor of critical steps in angiogenesis progression. FASEB J. 2000;14:2477-2485.
5. Yoshida D, Noha M, Watanabe K, et al. Novel approach to analysis of in vitro tumor angiogenesis with a variablepressure scanning electron microscope: Suppression by matrix metalloproteinase inhibitor SI-27. Brain Tumor Pathol. 2001;18:89-100.
6. Kaliski A, Maggiorella L, Cengel KA, et al. Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther. 2005;4:1717-1728.
7. Chang SH, Kanasaki K, Gocheva V, et al. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009;69:4537-4544.
8. van Hinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: Matrix metalloproteinases in the lead. Cardiovasc Res. 2008;78:203-212.
9. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2006;26:716-728.
10. Staton CA, Stribbling SM, Tazzyman S, et al. Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol. 2004;85:233-248.
11. Kwon YS, Hong HS, Kim JC, et al. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci. 2005;46:454-460.
12. Damms T, Ross JR, Duplessie MD, et al. Intracorneal bovine albumin: An immunologic model of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol. 1997;235:662-666.
13. Rogers MS, Birsner AE, D'Amato RJ. The mouse cornea micropocket angiogenesis assay. Nat Protoc. 2007;2:2545-2550.
14. Jia WD, Xu GL, Sun HC, et al. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo. Hepatobiliary Pancreat Dis Int. 2003;2:404-409.
15. Davis GE, Senger DR. Endothelial extracellular matrix: Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res. 2005;97:1093-1107.
16. Milde F, Bergdorf M, Koumoutsakos P. A hybrid model for three-dimensional simulations of sprouting angiogenesis. Biophys J. 2008; 95:3146-3160.
17. Chang SH, Kanasaki K, Gocheva V, et al. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009;69:4537-4544.
18. Kalluri R. Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003;3:422-433.
19. Zucker S, Mirza H, Conner CE, et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer. 1998;75: 780-786.
20. Bauer AL, Jackson TL, Jiang Y. Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS Comput Biol. 2009;5: e1000445.
21. Karagiannis ED, Popel AS. Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: Insights from a computational model. J Theor Biol. 2006;238:124-145.
22. Simizu S, Ishida K, Osada H. Heparanase as a molecular target of cancer chemotherapy. Cancer Sci. 2004;95:553-558.
23. Dreyfuss JL, Regatieri CV, Jarrouge TR, et al. Heparan sulfate proteoglycans: Structure, protein interactions and cell signaling. An Acad Bras Cienc. 2009;81:409-429.
24. Sanderson RD, Yang Y, Kelly T, et al. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies. J Cell Biochem. 2005;96:897-905.
25. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006;38:2018-2039. (Pubitemid 44397619)
26. Parish CR, Freeman C, Hulett MD. Heparanase: A key enzyme involved in cell invasion. Biochim Biophys Acta. 2001;1471:M99-M108.
27. Vlodavsky I, Goldshmidt O, Zcharia E, et al. Molecular properties and involvement of heparanase in cancer progression and normal development. Biochimie. 2001;83:831-839. (Pubitemid 32821249)
28. Vlodavsky I, Ilan N, Naggi A, et al. Heparanase: Structure, biological functions, and inhibition by heparin- derived mimetics of heparan sulfate. Curr Pharm Des. 2007;13:2057-2073.
29. Miao HQ, Liu H, Navarro E, et al. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem. 2006;13:2101-2111.
30. Puré E. The road to integrative cancer therapies: Emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer. Expert Opin Ther Targets. 2009;13:967-973.
31. Fassnacht M, Lee J, Milazzo C, et al. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: Implication for cancer immunotherapy. Clin Cancer Res. 2005;11:5566-5571.
32. Cheng JD, Weiner LM. Tumors and their microenvironments: Tilling the soil. Clin Cancer Res. 2003;9:1590-1595.
33. Bhati R, Patterson C, Livasy CA, et al. Molecular characterization of human breast tumor vascular cells. Am J Pathol. 2008;172:1381-1390.
34. Wang T, Shi W. Expression of fibroblast activation proteins in corneal stromal neovascularization. Curr Eye Res. 2009;34:112-117.